POSITIVE SELECTION SYSTEMS USING MARKER GENES

使用标记基因的正选择系统

• 批准号: 6935451
• 负责人: JOHN J NALEWAY
• 金额: $ 9.99万
• 依托单位: MARKER GENE TECHNOLOGIES
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6935451
• 关键词: beta lactamase; biosensor device; biotechnology; cell growth regulation; cell population study; cephalosporins; chemical conjugate; chemical synthesis; drug delivery systems; drug design /synthesis /production; enzyme inhibitors; flow cytometry; fusion gene; gene expression; gene targeting; gene therapy; genetic techniques; growth inhibitors; hematopoiesis; high performance liquid chromatography; leukopoiesis; reporter genes; technology /technique development; tissue /cell culture; tissue engineering; transfection

This Small Business Innovation Research Phase I project aims to investigate the feasibility of developing new compounds capable of utilizing common marker gene expression in transformed cells to control the growth and character of cells in cell culture and live tissue applications. If successful, the proposed research will provide breakthroughs needed to advance the promising medical uses of recombinant genes. In Phase I of this project, Marker Gene Technologies proposes to establish the feasibility of the technology by preparing new galactoside and Cephalosporin conjugates of common growth regulators, drugs and enzyme activators, for administration to animal cells or bacteria that contain either the beta-galactosidase (lacZ) or ampicillin resistance (Beta-lactamase, amp) genes as gene fusion markers. These new conjugates will be used to provide innovative methods of utilizing these fusion systems in transformed cells - to select for transgenic cells in a non-destructive fashion. In Phase I, the new conjugates will be assayed in vitro for their ability to cause specific and localized improvement of cell growth and to deliver the active agents in a cell- or tissue-specific manner. In Phase II, the conjugates will be further tested in a variety of significant medical applications. The success of this project opens up enormous commercial possibilities in the fields of cell selection, medical intervention in genetic diseases, immunotherapy for cancer treatment, biotechnological production of new proteins and drugs in cell-culture systems, and bacterial screening strategies, and the conjugates prepared can be marketed in these areas. In addition, it contributes new information and techniques for basic cell-biology research.

该小型企业创新研究第一阶段项目旨在研究开发能够利用转化细胞中常见标记基因表达的新化合物的可行性，以控制细胞培养和活组织应用中细胞的生长和特性。如果成功的话，这项研究将为推进重组基因的有前途的医学用途提供突破。 在该项目的第一阶段，标记基因技术公司提出建立的可行性， 通过制备常见生长调节剂、药物和酶激活剂的新半乳糖苷和头孢菌素缀合物的技术，用于对含有β-半乳糖苷酶（lacZ）或氨苄青霉素抗性（β-内酰胺酶，amp）基因作为基因融合标记的动物细胞或细菌给药。这些新的缀合物将用于提供在转化细胞中利用这些融合系统的创新方法-以非破坏性方式选择转基因细胞。 在I期，将在体外测定新缀合物引起细胞生长的特异性和局部改善以及以细胞或组织特异性方式递送活性剂的能力。在第二阶段，结合物将在各种重要的医学应用中进行进一步测试。 该项目的成功在细胞选择、遗传疾病的医学干预、癌症治疗的免疫疗法、细胞培养系统中新蛋白质和药物的生物技术生产以及细菌筛选策略等领域开辟了巨大的商业可能性，所制备的缀合物可以在这些领域销售。此外，它还为基础细胞生物学研究提供了新的信息和技术。